NCT07306390尚未招募不适用
Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences2 个研究点 分布在 1 个国家目标入组 1,200 人开始时间: 2026年7月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 1,200
- 试验地点
- 2
- 主要终点
- The spatial distribution of metastatic lymph nodes
研究概览
简要总结
The goal of this observational study is to learn about the spatial distribution and significance of metastatic lymph nodes in colorectal cancer patients. The main question it aims to answer is:
- What is the spatial distribution pattern of metastatic lymph nodes in patients with colorectal cancer?
- Can the spatial distribution pattern of metastatic lymph nodes in patients with colorectal cancer guide clinical practice? Participants should undergo regular follow-up examinations for at least 5 years after the surgery.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged between 18 and 80 years
- •Pathologically confirmed adenocarcinoma of the colon or rectum
- •Underwent radical resection for colorectal cancer with a D3 lymphadenectomy and lymph nodes were submitted for pathological examination according to standardized station-based and distance-based protocol
- •No distant metastasis or distant metastasis within 6 months after surgery
- •No history of other malignant tumors or severe systemic diseases
- •No immune diseases or inflammatory bowel diseases
- •Non-emergency surgery
- •With complete clinicopathological and follow-up data
排除标准
- •Pathologically confirmed benign tumors or non-adenocarcinoma malignancies
- •Underwent local excision or palliative resection
- •Regional lymph nodes were not dissected or submitted for pathological examination according to the unified station-based or distance-based protocol
- •With distant metastasis or distant metastasis within 6 months after surgery
- •Dual or multiple primary colorectal cancers or concurrent other malignant tumors
- •Had a previous diagnosis of immune diseases or inflammatory bowel disease such as ulcerative colitis or Crohn's disease
- •Underwent emergency surgery
- •Had incomplete clinicopathological or follow-up data
结局指标
主要结局
The spatial distribution of metastatic lymph nodes
时间窗: From enrollment to 14 days after surgery (at the completion of postoperative pathological examination)
次要结局
- Disease-free survival(From date of surgery until the date of first documented local recurrence, distant metastasis, or date of death from any cause, whichever came first, assessed up to 60 months)
- Overall survival(From date of surgery until the date of death from any cause, whichever came first, assessed up to 60 months)
研究者
HAI ZENG ZHAGN
Medical Doctor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants with Parkinson’s Disease (LUMA)MedDRA version: 20.0Level: PTClassification code: 10061536Term: Parkinson's disease Class: 100000004852Parkinson's DiseaseCTIS2023-505645-12-00Biogen Idec Research Limited523
进行中（未招募）
1 期
A Multicenter, Randomised, Double blind, Parallel, Phase III Global Study to Assess the Efficacy and Safety of BP01 (Bevacizumab) when compared to Avastin®-EU in Combination with Carboplatin and Paclitaxel during Induction phase and Bevacizumab alone during the Maintenance phase in patients with newly diagnosed or recurrent Stage IIIB/IV Non Squamous (ns) Non-Small Cell Lung Cancer (NSCLC).ewly diagnosed or recurrent Stage IIIB/IV Non Squamous (ns) Non-Small Cell Lung Cancer (NSCLC).MedDRA version: 20.0Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005618-16-HUCuraTeQ Biologics Private Limited648
招募中
3 期
Phase III Global Study to Assess the Efficacy and Safety of Bevacizumab compared to Avastin in Combination with Carboplatin and Paclitaxel during Induction phase and Bevacizumab alone during the Maintenance phase in patients with Stage IIIB/IV Lung CancerCTRI/2021/10/037247CURATEQ BIOLOGICS PRIVATE LIMITED India
进行中（未招募）
2 期
Evaluation of combination of Minoxidil (5%) and Adenosine (1%) topical solution in the treatment of Hair LossCTRI/2019/10/021835Dr Reddys Laboratories Limited
进行中（未招募）
不适用
Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12-Week Treatment with ASP1941 in Combination with Metformin in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone - The BALANCE StudyMedDRA version: 12.1Level: HLGTClassification code 10018424Term: Glucose metabolism disorders (incl diabetes mellitus)Type 2 Diabetes MellitusEUCTR2009-013881-25-GBAstellas Pharma Europe B.V.630